Eli Lilly and Company's weight-loss drugs received another boost Tuesday as a study revealed that it can can reduce the risk of developing Type 2 diabetes among obese and overweight adults with pre-diabetes by 94%.
According to CNBC, the active ingredient tirzepatide, which is found in Zepbound, the weight loss injection, and Mounjaro, the diabetes drug, was found to have helped patients in experiencing sustained weight loss in a span of a three-year treatment period.
